{
  "docId": "019de070-7de1-7343-8d2f-5d51a9877c50",
  "docSlug": "ff3158b4501b6094038126272ca46097",
  "documentTitle": "BioAtla | IPO Presentation Deck | 31 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 16,
  "pageCount": 31,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a numbered list for the strategic rationale and a table for the market sizing data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-7de1-7343-8d2f-5d51a9877c50/16",
  "deckHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50",
  "deckJsonHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50.json",
  "deckAnchorHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "1. Over-expressed across many solid tumors, including NSCLC, melanoma, ovarian, TNBC, and HNC. 2. Enhanced ROR2 expression with prior PD-1/L1 treatment. 3. No other ROR2 ADC or small molecules in the clinic yet, but competition is emerging.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a06fd08-264b-4d24-b9a0-c3457628a8e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: BioAtla IHC assay validation results & phase 1 AXL testing data, GlobalData-Opportunity Analysis and Forecasts, SEER database; Based on TmPS (Tumor membrane Percent Score) 75% of these patients generally switch to a new therapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7512a84e-c6b7-44f1-bb94-3a797d7f6f6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "table",
      "text": "Initial US Addressable Patient Population table with columns: Tumor type, Patient treatment phase, Est. corresponding US patient population, Est. ROR2 positivity rate, Est. US target population at launch.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf4fdbd2-afe0-421a-8805-de77c1d8bd01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "ROR2 Targeting: Significant Commercial Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ceebc28-7b19-47e0-93df-cfd2a80de92a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "ba29ba50-b264-4426-a66f-edfebcc14930",
      "evidence": "table/data: Initial US Addressable Patient Population table with columns: Tumor type, Patient treatment phase, Est. corresponding US patient population, Est. ROR2 positivity rate, Est. US target population at launch.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "9d99f51a-8525-43ca-8e4a-0df32037f34f",
      "evidence": "Breakdown of total addressable population by tumor type and treatment phase.",
      "confidence": 0.6
    }
  ],
  "arcBeats": [
    {
      "to": 21,
      "from": 12,
      "beatId": "2003e560-8567-434b-89b9-686dbf1d7731",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document presents traction information on pages 12-21.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}